Onderzoeker
Q Lecocq
- Onderzoeksexpertise:
Expertise: Tumor immunology.
We evaluate the use of single domain antibodies (sdAbs), also known as nanobodies, as targeting moieties for therapeutic and diagnostic applications.
- Trefwoorden:Geneeskunde
- Disciplines:Toegepaste immunologie, Kankertherapie
- Gebruikers van onderzoeksexpertise:
Expertise: Tumor immunology.
We evaluate the use of single domain antibodies (sdAbs), also known as nanobodies, as targeting moieties for therapeutic and diagnostic applications.
Affiliaties
- Laboratorium voor Moleculaire en Cellulaire Therapie (Onderzoeksgroep)
Verantwoordelijke
Vanaf19 mrt 2021 → Heden - Basis (bio)-medische wetenschappen (Departement)
Verantwoordelijke
Vanaf1 okt 2016 → 30 sep 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf18 aug 2016 → 23 nov 2021 - Faculteit van de Geneeskunde en Farmacie (Faculteit)
Lid
Vanaf31 aug 2014 → 21 jun 2016
Projecten
1 - 1 of 1
- Nanobody gemedieerde beeldvorming en blokkering van de inhiberende receptor LAG-3Vanaf1 jan 2018 → 31 dec 2021Financiering: FWO mandaten
Publicaties
1 - 10 van 21
- Targeted radionuclide therapy with low and high-dose Lutetium-177 labeled single domain antibodies induces distinct immune signatures in a mouse melanoma model(2022)
Auteurs: Thomas Ertveldt, Lien De Beck, Kirsten De Ridder, Hanne Locy, Wout de Mey, C Goyvaerts, Quentin Lecocq, Hannelore Ceuppens, Y De Vlaeminck, Robin Maximilian Awad, et al.
Pagina's: 1136-1148 - Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma(2022)
Auteurs: Lien De Beck, Robin Maximilian Awad, Veronica Basso, Noelia Casares, Kirsten De Ridder, Y De Vlaeminck, Alessandra Gnata, C Goyvaerts, Quentin Lecocq, Edurne San José-Enériz, et al.
- TNF-alpha-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy(2022)
Auteurs: Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, Robin Maximilian Awad, Stefaan Verhulst, Mathias Van Bulck, Y De Vlaeminck, Quentin Lecocq, Eva Reijmen, et al.
- Emerging applications of nanobodies in cancer therapy(2022)
Auteurs: Robin Maximilian Awad, Fien Meeus, Hannelore Ceuppens, Thomas Ertveldt, Heleen Hanssens, Quentin Lecocq, Lukasz Mateusiak, Katty Zeven, Hana Valenta, Timo W M De Groof, et al.
Pagina's: 143-199 - Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer(2021)
Auteurs: Quentin Lecocq, Pieterjan Debie, Janik Puttemans, Robin Maximilian Awad, Lien De Beck, Thomas Ertveldt, Y De Vlaeminck, C Goyvaerts, Geert Raes, M Keyaerts, et al.
- Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade(2021)
Auteurs: Quentin Lecocq, Robin Maximilian Awad, Y De Vlaeminck, Wout de Mey, Thomas Ertveldt, C Goyvaerts, Geert Raes, Kris Thielemans, M Keyaerts, Nick Devoogdt, et al.
Pagina's: 1638-1644 - Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade(2021)
Auteurs: Robin Maximilian Awad, Quentin Lecocq, Katty Zeven, Thomas Ertveldt, Lien De Beck, Hannelore Ceuppens, Katrijn Broos, Y De Vlaeminck, C Goyvaerts, Magali Verdonck, et al.
Pagina's: 172-182 - Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry(2021)
Auteurs: Dora Mugoli Chigoho, Quentin Lecocq, Robin Maximilian Awad, Karine Breckpot, Nick Devoogdt, M Keyaerts, Vicky Caveliers, Catarina Xavier, Jessica Bridoux
- Developing nanobodies to advance immune checkpoint therapy that targets lymphocyteactivation gene 3(2021)
Auteurs: Quentin Lecocq
Aantal pagina's: 170 - The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology(2020)
Auteurs: Quentin Lecocq, M Keyaerts, Nick Devoogdt, Karine Breckpot
Pagina's: 1-17
Patenten
1 - 2 van 2
- Human pd-l1-binding immunoglobulins (Inventor)
- Human pd-l1-binding immunoglobulins (Inventor)